Cargando…

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study

Melanoma is a relatively rare disease worldwide; nevertheless, it has a great relevance in some countries, such as in Europe. In order to shed some light upon the transcriptional profile of skin melanoma, we compared the gene expression of six independent tumours (all progressed towards metastatic d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lastraioli, Elena, Ruffinatti, Federico Alessandro, Bagni, Giacomo, Visentin, Luca, di Costanzo, Francesco, Munaron, Luca, Arcangeli, Annarosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266837/ https://www.ncbi.nlm.nih.gov/pubmed/35805902 http://dx.doi.org/10.3390/ijms23136898

Ejemplares similares

A Transcriptomic Approach Reveals Selective Ribosomal Remodelling in the Tumour Versus the Stromal Compartment of Metastatic Colorectal Cancer
por: Lastraioli, Elena, et al.
Publicado: (2021)

Corrigendum to “Transcriptomic data of Bevacizumab-adapted colorectal adenocarcinoma cells HCT-116” [Data In Brief, Volume 48, (Available online 17 March 2023) 1-9/Article 109069]
por: Sala, Cesare, et al.
Publicado: (2023)

BioTEA: Containerized Methods of Analysis for Microarray-Based Transcriptomics Data
por: Visentin, Luca, et al.
Publicado: (2022)

The role of ion channels and transporters in cell proliferation and cancer
por: Becchetti, Andrea, et al.
Publicado: (2013)

K(V)11.1 Potassium Channel and the Na(+)/H(+) Antiporter NHE1 Modulate Adhesion-Dependent Intracellular pH in Colorectal Cancer Cells
por: Iorio, Jessica, et al.
Publicado: (2020)

KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation
por: Lastraioli, Elena, et al.
Publicado: (2021)

Immunohistochemical Biomarkers in Gastric Cancer Research and Management
por: Lastraioli, Elena, et al.
Publicado: (2012)

hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients()
por: Iorio, Jessica, et al.
Publicado: (2020)

hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy
por: Muratori, Leonardo, et al.
Publicado: (2016)

Circulating miRNome profiling data in Behçet's syndrome
por: Bagni, Giacomo, et al.
Publicado: (2021)

A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome
por: Emmi, Giacomo, et al.
Publicado: (2022)

Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
por: Lastraioli, Elena, et al.
Publicado: (2023)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Isolation and Characterization of Buccal Fat Pad and Dental Pulp MSCs from the Same Donor
por: Genova, Tullio, et al.
Publicado: (2021)

hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers
por: Lastraioli, Elena, et al.
Publicado: (2015)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients
por: Frankel, Arthur E., et al.
Publicado: (2017)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Integrins regulate hERG1 dynamics by girdin-dependent Gαi3: signaling and modeling in cancer cells
por: Duranti, Claudia, et al.
Publicado: (2023)

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
por: Vanni, Irene, et al.
Publicado: (2020)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Circulating Endothelial Progenitor Cells in Type 1 Diabetic Patients: Relation with Patients’ Age and Disease Duration
por: Arcangeli, Adolfo, et al.
Publicado: (2017)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

hERG1 Potassium Channel Expression in Colorectal Adenomas: Comparison with Other Preneoplastic Lesions of the Gastrointestinal Tract
por: Lastraioli, Elena, et al.
Publicado: (2022)

Correction: Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K
por: Petroni, Giulia, et al.
Publicado: (2020)

Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K
por: Petroni, Giulia, et al.
Publicado: (2020)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
por: Flockhart, R J, et al.
Publicado: (2009)

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
por: Garrisi, Vito Michele, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s2bin3l9uteicjdd50f8pio696